Across TCGA pan-cancer cohorts, SLC35E2B mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of SLC35E2B’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where SLC35E2B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SLC35E2B is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

LUAD and LSCC are the cancer types where SLC35E2B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC35E2B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	All	−0.779	.001	4	view →
LSCC	All	II,III,IV	−0.650	.019	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: SLC35E2B RNA expression & survival · all SLC35E2B data types